Pipeline and R&D programs

In 2013, Ipsen’s R&D expenditure totaled close to €259.1 million, representing more than 21% of Group sales.

Ipsen’s R&D activities are focused on the discovery and development of new molecules and on programs for the lifecycle management of products already marketed by the group (new formulations, extension of indications and registration of products in new geographical areas).

 Phase IPhase IIPhase III
Neurology

BN82451

Symptoms of Huntington’s disease
Yes

DYSPORT®

Muscle spasticity of lower limbs in adults
Yes

DYSPORT® 

Muscle spasticity of upper limbs in adults
Yes

DYSPORT®

Muscle spasticity of lower limbs in children
Yes

DYSPORT®

Muscle spasticity of upper limbs in children
Yes

DYSPORT®

Neurogenic detrusor overactivity
Yes

DYSPORT® NEXT GENERATION

Temporary correction of moderate to severe glabellar lines in adults
Yes

DYSPORT® NEXT GENERATION

Cervical dystonia
Yes
Endocrinology

SOMATULINE®

Nonfunctioning neuroendocrine tumors – international study (Clarinet)
Yes

somatuline®

Functioning neuroendocrine tumors – US study (Elect)
Yes
Urology-Oncology

DECAPEPTYL®

Evaluation of the efficacy and tolerance of the 3-month pamoate subcutaneous formulation
Yes

DECAPEPTYL®

Combined hormone therapy for pre-menopausal breast cancer
Yes

TAQUINIMOD

Castration-resistant prostate cancer – Asia
Yes

Tasquinimod

Castration-resistant prostate cancer
(conducted by Active Biotech)
Yes

TASQUINIMOD

Maintenance therapy after chemotherapy in prostate cancer
Yes

TASQUINIMOD

Hepato-cellular, ovarian, renal cell and gastric cancers
Yes

* at February 28, 2014